A multicenter phase 3 clinical trial is being conducted to study the efficacy and safety of a clinical trial drug (Romosozumab) compared to bisphosphonates in children and adolescents who have OI.  The trial is open to eligible children from age 5 to less than 18 years of age who have a diagnoses of OI Type I through IV. The clinical trial will have sites participating in the following countries: Canada, United States, Australia, China, Japan, Austria, Belgium, Italy, Hungary, Poland, Slovakia, Switzerland, France, Germany, Spain, Turkey and the United Kingdom.

For more information, please visit the clinical trial registry page at https://clinicaltrials.gov/study/NCT05972551.

Oregon Health and Science University is conducting a survey to understand the prevalence and impact of skin symptoms in individuals with osteogenesis imperfecta (OI). As we know, OI is a disorder that affects bones and connective tissues, but its implications on skin health are less understood. By sharing your experiences, you can help bridge this knowledge gap. The surveys are brief, and each should take no more than 10 minutes of your time. Your responses will be kept confidential and used solely for research purposes.

Click here to participate

Thank you in advance for your valuable contribution to this important study. For questions, please contact study staff at [email protected].